1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Patrys Limited
  6. News
  7. Press Releases
    PAB   AU000000PAB9

PATRYS LIMITED

(PAB)
Delayed Australian Stock Exchange  -  02:10 2022-08-10 am EDT
0.0260 AUD   +8.33%
04:10aPatrys Validates Efficacy of Brain Cancer Drug in Preclinical Animal Study
MT
08/07Patrys Chair to Retire End-August
MT
07/27PATRYS : Appendix 4C - Quarterly - 30 June 2022
PU
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société PATRYS LIMITED
07/27PATRYS : Appendix 4C - Quarterly - 30 June 2022
PU
04/27PATRYS : Appendix 4C - Quarterly - 31 March 2022
PU
04/14PATRYS : Application for quotation of securities - PAB
PU
03/23NEW RESEARCH : Scientists determine structure of a DNA damage ‘First Responder' prot..
PU
02/24PATRYS : Appendix 4D - Half Year Accounts - 31 December 2021
PU
02/07PATRYS : Application for quotation of securities - PAB
PU
02/07PATRYS : ADC Deals Making Headlines
PU
01/30PATRYS : Appendix 4C - Quarterly - 31 December 2021
PU
2021PATRYS : Ceasing to be a substantial holder from MQG
PU
2021PATRYS : Application for quotation of securities - PAB
PU
2021PATRYS : Change of Director's Interest Notices x2
PU
2021PATRYS : Application for quotation of securities - PAB
PU
2021PATRYS : Notification regarding unquoted securities - PAB
PU
2021PATRYS : Notification regarding unquoted securities - PAB
PU
2021Becoming a substantial holder from MQG
PU
2021Rights Issue Offer Document
PU
2021PATRYS LIMITED : Announces Publication of PAT-DX1 Preclinical Data in JCI - Insight
BU
2020PATRYS : Adds Full Human Antibody to Deoxymab Portfolio
PU
2020PATRYS : Adds Full Human Antibody to Deoxymab Portfolio
PU
2020PATRYS : Entitlement Offer Results and Shortfall Notification
PU
2020PATRYS : New Appointment to Scientific Advisory Board
PU
2019PATRYS : Annual Report 2019
PU
2019PATRYS : Presented at Leading Brain Metastases Conference
PU
2019PATRYS : Updated Investor Presentation and Attendance at Bioshares
PU
2019PATRYS : PAT-DX1 Significantly Improves Survival in Aggressive GBM
PU
2019PATRYS : Europe Grants Patent for Deoxymab 3E10
PU
2019PATRYS : Presentation at AACR Conference
PU
2019PATRYS : Presenting at Biotech Showcase
PU
2019PATRYS : Receives R&D Tax Incentive Refund
PU
2018PATRYS : PAT-DX1 Suppresses Breast Cancer Brain Metastases
PU
2018PATRYS : Notice of Annual General Meeting/ Proxy Form
PU
2018PATRYS : and Yale Awarded Grant
PU
2018PATRYS : and WEHI Awarded Grant
PU
2018PATRYS : China and Japan Both Grant Patents for Deoxymab 3E10
PU
2018PATRYS : PAT-DX1 Targets and Kills Brain Cancer Stem Cells
PU
2018PATRYS : Increases Capital Raising to $4.6 Million
PU
2018PATRYS : Announcement of $3.5 Million Share Placement
PU
2018PATRYS : Presents at AACR Conference
PU
2018PATRYS : Publication and Patent Filing for Humanized Version of Deoxymab 3E10
PU
2018PATRYS : PAT-DX1-NP Localizes to Lymph Node Metastases
PU
2017PATRYS : PAT-DX1 Synergistic with PARP Inhibitor
PU
2017PATRYS : PAT-DX1 Active in Pre-clinical Cancer Models
PU
2017PATRYS : rsquo; Deoxymab 3E10 Patent Granted in the U.S.
PU
2017PATRYS : 8 June 2017 – Investor Update
PU
2017PATRYS : 1 May 2017 – Finance Update
PU
2017PATRYS : 19 April 2017 – Deoxymab 3E10 Lead Candidate Confirmed
PU
2016PATRYS : 13 December 2016 – Appointments ot New Scientific Advisory Board
PU
2016PATRYS : 26 September 2016 – Business Review June 2016
PU
2016PATRYS : 30 August 2016 - Appendix 4G & Corporate Governance Statement
PU
2016PATRYS : 30 August 2016 - Appendix 4E & 2016 Annual Report
PU
2016PATRYS : 29 March 2016 - Patrys Acquires License to Novel Nucleus-Pentrating Antibody Asse..
PU
2015PATRYS : 11 November 2015 - Results of Meeting
PU
2015PATRYS : 11 November 2015 - AGM Presentation
PU
2015PATRYS : 27 October 2015 - Appendix 4C - Quarterly 30 September 2015
PU
2015PATRYS : 8 October 2015 - Corporate Governance Statement
PU
2015PATRYS : 30 September 2015 - Corporate Restructure & Change in Company Secretary
PU
2015PATRYS : 29 September 2015 - Market Update
PU
2015PATRYS : 11 September 2015 - Change of Registered Office
PU
2015PATRYS : 14 July 2015 - Appendix 4C -Quarterly 30 June 2015
PU
2015PATRYS : 25 June 2015 - Patrys to License Chinese Rights for PAT-SC1
PU
2015PATRYS : 11 June 2015 - Further Manufacturing Update
PU
2015PATRYS : 1 May 2015 - Announcement of Buy-back - Appendix 3C
PU
2015PATRYS : 19 May 2015 - Final Share Buy-back Notice - Appendix 3F
PU
2015PATRYS : 19 May 2015 - Daily Share Buy-back Notice - Appendix 3E
PU
2015PATRYS : 2 May 2015 - Announcement of Buy-back - Appendix 3C
PU
2015PATRYS : 20 April 2015 - Appendix 4C -Quarterly 31 March 2015
PU
2015PATRYS : 8 April 2015 - Patrys Appoints Dr. James Campbell as CEO
PU
2015PATRYS : 18 February 2015 - Patrys Granted European Patent for PAT-SM6
PU
2014PATRYS : 12 November 2014 - Initial Director's Interest Notice - J Campbell
PU
2014PATRYS : 12 November 2014 - Dr. James Campbell Joins the Patrys Board
PU
2014PATRYS : 12 November 2014 - AGM 2014 Results of Meeting
PU
2014PATRYS : 12 November 2014 - AGM Presentation 2014
PU
2014PATRYS : 29 October 2014 - Update on CEO Position
PU
2014PATRYS : 17 October 2014 - Appendix 4C- Quarterly Cash Flow-Sept 2014
PU
2014PATRYS : 30 September 2014 - Patrys Granted Australian Patent for PAT-LM1
PU
1  2Next
Upcoming event on PATRYS LIMITED